Janssen re­ports de­cline in 2022 net prices as out-of-pock­et costs grow

While net prices for Janssen’s com­mer­cial drugs have de­clined for the sixth con­sec­u­tive year, out-of-pock­et costs have con­tin­ued to rise for some pa­tients, ac­cord­ing to the com­pa­ny’s lat­est US Pric­ing Trans­paren­cy Re­port.

The com­pa­ny pro­vid­ed $39 bil­lion last year in the form of re­bates, dis­counts and fees to com­mer­cial health in­sur­ers, phar­ma­cy ben­e­fit man­agers and oth­er in­ter­me­di­aries, it said in the re­port — a more than $5 bil­lion in­crease com­pared to 2021. A ma­jor­i­ty of that, or $11.2 bil­lion, went to com­mer­cial pay­ers and PBMs, while 16% (or $6.2 bil­lion) went to the 340B pro­gram, 13% ($5.1 bil­lion) went to Medicare and 10% ($3.8 bil­lion) to Med­ic­aid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER